H.C. Arentsen
About
H.C. Arentsen is a scholar working on Surgery, Biotechnology and Urology.
According to data from OpenAlex, H.C. Arentsen has authored 25 papers receiving a total of 290 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Surgery, 6 papers in Biotechnology and 5 papers in Urology. Recurrent topics in H.C. Arentsen's work include Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (8 papers) and Cancer Research and Treatments (6 papers). H.C. Arentsen is often cited by papers focused on Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (8 papers) and Cancer Research and Treatments (6 papers). H.C. Arentsen collaborates with scholars based in Netherlands, Belgium and Italy. H.C. Arentsen's co-authors include J. Alfred Witjes, Egbert Oosterwijk, Theo M. de Reijke, Kees Hendricksen, Erik B. Cornel, Dirk Zaak, Marko Babjuk, Per‐Uno Malmström, D. Jocham and Francesco Montorsi and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.
In The Last Decade
H.C. Arentsen
22 papers receiving 281 citations
Peers
H.C. Arentsen
Weidong Xu China
F. Johannes P. van Valenberg Netherlands
J.P. Burgués Spain
Ch. Bouffioux Belgium
Roberto Carando Italy
Wenxi Tan China
Xiaofeng Yang China
BERND POSCH Austria
Megan K. Fuller United States
Bianca Oresta Italy
Citations per year, relative to H.C. Arentsen H.C. Arentsen (= 1×)
peers
Weidong Xu
Countries citing papers authored by H.C. Arentsen
Since
Specialization
Citations
This map shows the geographic impact of H.C. Arentsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.C. Arentsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.C. Arentsen more than expected).
Fields of papers citing papers by H.C. Arentsen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by H.C. Arentsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.C. Arentsen. The network helps show where H.C. Arentsen may publish in the future.
Co-authorship network of co-authors of H.C. Arentsen
This figure shows the co-authorship network connecting the top 25 collaborators of H.C. Arentsen. A scholar is included among the top collaborators of H.C. Arentsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.C. Arentsen. H.C. Arentsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Daneshmand, Siamak, Christopher Pieczonka, Giuseppe Simone, et al.. (2025). SAFETY AND TOLERABILITY OF TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN (BCG)-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) IN SUNRISE-1. Urologic Oncology Seminars and Original Investigations. 43(3). 55–55.
2.
Heijden, Michiel S. van der, Martin Boegemann, Félix Guerrero‐Ramos, et al.. (2024). LBA85 TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1). Annals of Oncology. 35. S1272–S1273.
3.
Heijden, Michiel S. van der, Félix Guerrero‐Ramos, Siamak Daneshmand, et al.. (2024). LB003 TAR-200 +/- cetrelimab and cetrelimab alone in patients with bacillus Calmette- Guérin–unresponsive high-risk non–muscle-invasive bladder cancer: updated results from SunRISe-1. European Urology Open Science. 69. 4–5.
4.
Necchi, Andrea, Siamak Daneshmand, Giuseppe Simone, et al.. (2024). P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY. The Journal of Urology. 211(5S2).
5.
Jacob, Joseph M, Siamak Daneshmand, Giuseppe Simone, et al.. (2023). LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy. Annals of Oncology. 34. S1343–S1344.
6.
Daneshmand, Siamak, Michiel S. van der Heijden, Joseph M Jacob, et al.. (2023). LBA02-03 FIRST RESULTS FROM SunRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE. The Journal of Urology. 209(Supplement 4).
7.
Valenberg, F. Johannes P. van, Dalit Strauss‐Ayali, H.C. Arentsen, et al.. (2018). Assessment of the efficacy of repeated instillations of mitomycin C mixed with a thermosensitive hydrogel in an orthotopic rat bladder cancer model. Therapeutic Advances in Urology. 10(7). 213–221.
8.
Valenberg, F. Johannes P. van, et al.. (2016). 1048 Assessment of the efficacy of repeated instillations of TC-gel mixed with MMC in an invasive rat bladder cancer model. European Urology Supplements. 15(3). e1048–e1048.
9.
Arentsen, H.C., et al.. (2015). Management of Low-risk and Intermediate-risk Non–Muscle-invasive Bladder Carcinoma. Hematology/Oncology Clinics of North America. 29(2). 219–225.
10.
Arends, Tom J.H., Rianne J.M. Lammers, Diederik M. Somford, et al.. (2014). Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World Journal of Urology. 33(10). 1411–1417.
11.
Arentsen, H.C., et al.. (2013). The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: An in vitro study. Urologic Oncology Seminars and Original Investigations. 32(1). 49.e1–49.e6.
12.
Arentsen, H.C., et al.. (2012). 665 Pharmacokinetics and toxicity of R-837 and TMX-202 after intravesical and intravenous administration: A pre-clinical study in naive rats. European Urology Supplements. 11(1). e665–e665a.
13.
Arentsen, H.C., Cornelius F.J. Jansen, Christina A. Hulsbergen‐van de Kaa, et al.. (2012). Antitumor Effects of cis -Urocanic Acid on Experimental Urothelial Cell Carcinoma of the Bladder. The Journal of Urology. 187(4). 1445–1449.
14.
Lammers, Rianne J.M., H.C. Arentsen, M. Ravic, et al.. (2012). Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer. The Journal of Urology. 189(6). 2077–2082.
15.
Arentsen, H.C., Christina A. Hulsbergen‐van de Kaa, Cornelius F.J. Jansen, et al.. (2011). Pharmacokinetics and toxicity of intravesical TMX‐101: a preclinical study in pigs. British Journal of Urology. 108(7). 1210–1214.
16.
Witjes, J. Alfred, Juan Palou Redorta, Didier Jacqmin, et al.. (2010). Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non–Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations. European Urology. 57(4). 607–614.
17.
Arentsen, H.C., Cornelius F.J. Jansen, Christina A. Hulsbergen‐van de Kaa, et al.. (2010). 931 ANTITUMOUR EFFECTS OF CIS-UROCANIC ACID, AN INTRAVESICAL PROTODYNAMIC DRUG, IN EXPERIMENTAL UROTHELIAL CELL CARCINOMA OF THE BLADDER. European Urology Supplements. 9(2). 292–292.
18.
Arentsen, H.C., et al.. (2009). The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations. Urologic Oncology Seminars and Original Investigations. 30(1). 64–68.
19.
Arentsen, H.C., Kees Hendricksen, Egbert Oosterwijk, & J. Alfred Witjes. (2009). Experimental rat bladder urothelial cell carcinoma models. World Journal of Urology. 27(3). 313–317.
20.
Arentsen, H.C., Jean de la Rosette, Theo M. de Reijke, & S. Langbein. (2006). Fluorescencein situhybridization: a multitarget approach in diagnosis and management of urothelial cancer. Expert Review of Molecular Diagnostics. 7(1). 11–19.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Weidong Xu Breakdown of academic impact, for papers by F. Johannes P. van Valenberg Breakdown of academic impact, for papers by J.P. Burgués Breakdown of academic impact, for papers by Ch. Bouffioux Breakdown of academic impact, for papers by Roberto Carando Breakdown of academic impact, for papers by Wenxi Tan Breakdown of academic impact, for papers by Xiaofeng Yang Breakdown of academic impact, for papers by BERND POSCH Breakdown of academic impact, for papers by Megan K. Fuller Breakdown of academic impact, for papers by Bianca Oresta